Among the many topics covered in the comprehensive Q121 Soft Tissue Fixation Market Recap* are:

SmartTRAK highlights what’s new in orthopedics, sports medicine, wound care, regenerative medicine and neuro therapies, with a spotlight on Depuy Synthes, a subsidiary of J&J. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, research, financial data and competitor developments in the global life sciences industry.

The following is a sampling of some recent updates covering Depuy Synthes that were compiled, reviewed and posted in real-time by our SmartTRAK analysts.

New Products:

• DePuy Synthes will distribute Expanding Innovations’ X-Pac Expandable Lumbar Cage System in the US. The system allows for controlled expansion of both height and lordosis and post-packing of graft.
• In its Q420 earnings call, JNJ touted the FDA clearance of its VELYS Robotic-Assisted Solution for use w/ the ATTUNE* knee system. The Company will launch its VELYS robot for TKA in 2021, however, specific timing was not provided. JNJ Q420 Earnings Transcript on Seeking Alpha
• WFS analyst Larry Biegelsen notes that in addition to competitive advantages including small footprint, digital connectivity, short set-up time & small learning curve, JNJ’s VELYS robot is expected to be cost-effective w/ prior commentary suggesting a price point of ~$250K.
  
  

Sure you read the news, a blog or journal or two, but you do you ever truly feel like you know what your competition is up to? SmartTRAK does! We provide real-time market intel on the MedTech industry including trends, news, financial data, competitor developments and more.  Our platform is fueled by industry experts, all of whom have had years of previous experience working at some of the biggest players in the industry.  Our team knows what's important to you and we keep our eye to the competition 24/7-- so that our subscribers can save time and find all the competitive intel they need in one place.

SmartTRAK currently features profiles on an ever-growing growing list of over 7,000+ products, including product descriptions, classifications, indications, clinical updates, regulatory status, studies, reimbursements, sales and distribution and more. Learn more about SmartTRAK's competitor profiling below:

SmartTRAK also provides up-to-date, detailed company overviews, including the latest intel, revenues and financial outlooks, strategic alliances and more on over 1,100+ companies, and the list is growing daily. New to a particular industry, or looking to expand into new territory? SmartTRAK's company and product profiles can help you get the lay of the land quickly:

 

A subscription to SmartTRAK provides you with access to our comprehensive coverage of Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapies markets worldwide. In addition, all subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about   SmartTRAK , or to see if your company subscribes, just click the button below.

It's time to get out there again and re-connect, and SmartTRAK is excited to be attending ISASS21, the International Society for the Advancement of Spine Surgery's 21st annual conference, at the Loews Miami Beach Hotel in South Beach Miami, May 13-15.

SmartTRAK will be represented by Julianne Burns, General Manager, Spine. Please contact us if you would like a meeting.

Click to read some recent SmartTRAKanalysis articles by Julianne that were featured on the blog:

• Top Trends in Spine in 2021: A Market in Motion
• Spine's Next Big Biomaterial: DiFusion Technologies’ ZFUZE

Like the ball whirling around a casino roulette wheel, COVID-19 sent the US Joint Fluid Market players bouncing and spinning off widely, with some landing the year as winners, and others not so much.

Once again COVID-19 sent players spinning at dizzying speed around the roulette wheel, all in hopes that Lady Luck would let them land unscathed for Q420. With the continued pressure from COVID impacting recovery of the healthcare system and business operations, including the US Joint Fluid Replacement, total revenue for Q420 finished lower vs Q419, according to  SmartTRAK Financial Dashboard. 

Among the many topics covered in the comprehensive Q420/FY20 US Joint Fluid Market Recap* are:

We are excited to announce the addition of the full market view of Orthopedic Pediatrics (US) to the SmartTRAK platform, featuring 3 modules covering Pediatric Trauma, Pediatric Extremities and Pediatric Spine!

Coverage includes:

• Pediatric Trauma:
  • Pelvis
  • Femur
  • Proximal Tibia
    Technologies covered include Guided Growth Plates, Anatomic Plates, IM Nails (including Elastic Nails), Deformity Correction and more!

• Pediatric Extremities
  
  • Upper Extremities Fixation
  • Foot and Ankle Fixation
    Technologies featured include Cannulated Screws, Clavicle Plates, Wrist Fusion Plates, External Fixation and more!

• Pediatric Spine:
  • Adolescent idiopathic Scoliosis
  • Early Onset Scoliosis
  • Neuromuscular Scoliosis
    Technologies included feature Growing Rods, Fusion Technologies, Vertebral Body Tethering, ApiFix and more!

Aure Bruneau, CEO of Stimwave, discusses his vision for the Company and taking peripheral nerve stimulation to the next level in an interview with SmartTRAK

Since starting as CEO of Stimwave in April 2020, Aure Bruneau has brought a new vision, energy and focus to the Company.  In the last 12 months, the former Zimmer Biomet executive has been positioning Stimwave for growth, building a high performing team and rebuilding the foundation of the Company, touching almost every aspect of the business, including regulatory, quality, manufacturing operations, marketing, IT, compliance and R&D. Strategically, Bruneau has refined the Company’s spinal cord stimulation (SCS) strategy and shifted efforts toward peripheral nerve stimulation (PNS) where he believes the technology will have a more meaningful impact and a market opportunity as big as the existing SCS market. In fact, he estimates the PNS opportunity to be at least $1.5 billion to treat chronic pain just for selected musculoskeletal indications (shoulders, knees, feet, ankles and the SI joint).

Looking ahead, Stimwave is planning to launch new products and a series of clinical trials in 2021 to validate a new standard of care that will help take the Company’s PNS platform to the next level and help drive future growth.

To find out more, click on the following video (26:35 min) and listen to SmartTRAK’s interview with Bruneau recorded recently via Uberconference. A transcript of the complete interview is also available below.

SmartTRAK is pleased to announce the addition of the Deep Brain Stimulation (DBS) module to our business intelligence platform. The DBS module will provide real-time news and analysis of the US market for Deep Brain Stimulation, including an in-depth overview of the market and expert insight into the latest research, trends and innovation in DBS. 

"SmartTRAK is excited to offer this detailed analysis of the US DBS Market. By providing sophisticated market modeling and real-time monitoring of the competitive landscape, my goal is to provide must-have data and unparalleled insight that will help subscribing partners make informed strategic decisions and create innovative solutions that will ultimately improve patient care and drive results." Anne Staylor, SmartTRAK GM, Strategic Alignment & Neuro Therapies.

The Deep Brain Stimulation module includes:

With jockeys and their racehorses out of the gates to make up for the losses during H120, a resurge of COVID cases muddied the track again, slowing the finish to the 2020 Derby.

If the US Orthobio Market was off racing again in Q320, the racetrack got a bit muddy with a resurgence of positive COVID-19 cases, which halted or placed restrictions on elective procedures in some US states. Spine procedure volumes were particularly affected by the renewed restrictions in Q420, which had a domino effect of negatively impacting the Bone Replacement segment for Q4 and FY20, respectively.

Among the many topics covered in the comprehensive Q420/FY20 US Orthobio Market Recap* are:

A year of turbulence as COVID-19 affects the WW Advanced Wound Care market at different times and in a variety of ways throughout the year.

For FY20, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was down -1.9% YoY. Q420 grew +1.0%, reflecting the gradual recovery in the market.

Among the many topics covered in the comprehensive Q420/FY20 Advanced Wound Care Market Recap* are: